Carregant...
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer
The epothilone B analog, ixabepilone, demonstrates low susceptibility to drug resistance mechanisms and has demonstrated clinically meaningful efficacy in patients refractory to other chemotherapeutic options. Ixabepilone is approved by the FDA for treatment of patients with metastatic breast cancer...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer-Verlag
2010
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2955910/ https://ncbi.nlm.nih.gov/pubmed/20886213 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1467-x |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|